Effectiveness of 0.02% pentahydroxyethylnaphtoquinone (hystochrome) in patients with active and fibrous stages of retinopathy of prematurity

Abstract

Aim. To study the effectiveness and safety of pentahydroxyethylnaphtoquinone (Hystochrome) in patients with active and fibrous stages of retinopathy of prematurity. Methods. 281 prematurely born babies: first group - 63 patients with retinopathy of prematurity stages I-II and vast non-vascular area; second group - 201 baby with stage III retinopathy of prematurity and posterior aggressive form of retinopathy after the performed retinal laser photocoagulation; third group - 17 babies with subtotal intraocular hemorrhage - were followed up. In addition, 29 children with fibrous stage of retinopathy of prematurity were observed. Pentahydroxyethylnaphtoquinone (Hystochrome) was used as epibulbar instillations and peribulbar injections. To assess the treatment results, examination using the «RETCAM-120» system, B-scan ultrasonography using the «AVISO» scanner and visual evoked potentials examination with flash light stimulus using the «Neuro-MVP» device were performed. Results. In babies from the first group the improvement of electrophysiological parameters was observed in 20% of cases after treatment with pentahydroxyethylnaphtoquinone, compared to 4% in control group. In the second group pentahydroxyethylnaphtoquinone improved the electrophysiological parameters in 39% of cases. In the third group (17 babies with subtotal intraocular hemorrhage) the hemorrhage degradation was twice more rapid compared to controls. There was no effect from pentahydroxyethylnaphtoquinone treatment at the late stages of the disease. No adverse effects were registered. Conclusion. Pentahydroxyethylnaphtoquinone (Hystochrome) has shown good effectiveness and safety while treating patients with non-proliferative stages of retinopathy of prematurity and vitreous hemorrhage.

Multifaceted Clinical Effects of Echinochrome

“…The study showed that forced instillation of 0.02% of histochrome solution significantly reduced the occurrence of RP, especially stage III, and thus contributed to more favorable outcomes. The authors concluded that histochrome (pentahydroxyethylnaphthoquinone) was an effective and safe drug for the treatment of nonproliferative stages of retinopathy of prematurity and vitreous hemorrhage [ 30 ] ( Figure 2 ).…”

Implication of Echinochrome A in the Plasticity and Damage of Intestinal Epithelium

“…In the previous studies on CVDs, Ech A was mostly administered intravenously (IV), in line with the disease features requiring immediate action of drugs after disease onset and accessibility to the target lesion [15,16]. In line, subconjunctival or peribulbar injections have been employed for the treatment of ophthalmologic diseases due to the physical proximity and resulting effectiveness of drug delivery [17,18]. In addition, several other preclinical studies using animal models took subcutaneous (SC) or intraperitoneal (IP) routes depending on the experimental design or probably for ease of experiment [8,13,19,20].…”